Trial site
Eszak-Budai Szent Janos Centrumkorhaz
Budapest XII, 1125, HungaryEU-13 widening countryNot linked to an institution yet
- 3running trials
- 8closed trials
The trials here
What the 11 trials at this site are about, from their registry records.
- Phase
- Phase 39 trials
- Phase 21 trial
- Phase 2/31 trial
- Status
- Completed8 trials
- Recruiting2 trials
- Active, not recruiting1 trial
- Lead sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company2 trials
- DiaMedica Therapeutics Inc1 trial
- Diamyd Medical AB1 trial
- Eli Lilly and Company1 trial
- Faes Farma S.A.1 trial
- and 5 more
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Not yet recruiting
A Study to Learn About the Study Medicine Called Aztreonam-Avibactam in Neonates and Infants Less Than 9 Months of Age With Suspected or Confirmed Infections Due to Gram-Negative Bacteria
NCT06462235· Phase 2· Pfizer Inc.· Source
Completed
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and an Open- labeled Long-term Extension Treatment with Aticaprant
2024-511557-21-00· Phase 3· Janssen Cilag International· Source
Recruiting
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
NCT06585787· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source
Completed
A randomised, double-blind, double-dummy, multicentre, phase III, non inferiority trial of an oral mesalazine formulation in patients with active mild to moderate ulcerative colitis for the induction of remission.
NCT06176560· Phase 3· Faes Farma S.A.· Source
Recruiting
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
NCT05980949· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source
Active, not recruiting
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034· Phase 3· Janssen Research & Development, LLC· Source
Completed
A clinical study to investigate if the investigational drug Diamyd is safe and can preserve insulin production and secretion in adolescents and adults that have recently been diagnosed type 1 diabetes. The safety of Diamyd will also be investigated. Some subjects may receive a placebo drug.
NCT05018585· Phase 3· Diamyd Medical AB· Source
Completed
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
NCT04255433· Phase 3· Eli Lilly and Company· Source
Report an error